1. Home
  2. CCNE vs ABUS Comparison

CCNE vs ABUS Comparison

Compare CCNE & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCNE
  • ABUS
  • Stock Information
  • Founded
  • CCNE 1865
  • ABUS 2005
  • Country
  • CCNE United States
  • ABUS United States
  • Employees
  • CCNE N/A
  • ABUS N/A
  • Industry
  • CCNE Major Banks
  • ABUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCNE Finance
  • ABUS Health Care
  • Exchange
  • CCNE Nasdaq
  • ABUS Nasdaq
  • Market Cap
  • CCNE 775.5M
  • ABUS 711.2M
  • IPO Year
  • CCNE N/A
  • ABUS N/A
  • Fundamental
  • Price
  • CCNE $24.33
  • ABUS $4.34
  • Analyst Decision
  • CCNE Hold
  • ABUS Strong Buy
  • Analyst Count
  • CCNE 1
  • ABUS 2
  • Target Price
  • CCNE $29.00
  • ABUS $5.00
  • AVG Volume (30 Days)
  • CCNE 130.2K
  • ABUS 1.4M
  • Earning Date
  • CCNE 10-20-2025
  • ABUS 11-05-2025
  • Dividend Yield
  • CCNE 2.96%
  • ABUS N/A
  • EPS Growth
  • CCNE 2.16
  • ABUS N/A
  • EPS
  • CCNE 2.38
  • ABUS N/A
  • Revenue
  • CCNE $224,762,000.00
  • ABUS $15,416,000.00
  • Revenue This Year
  • CCNE $17.68
  • ABUS $138.02
  • Revenue Next Year
  • CCNE $30.32
  • ABUS N/A
  • P/E Ratio
  • CCNE $10.23
  • ABUS N/A
  • Revenue Growth
  • CCNE 4.79
  • ABUS 53.23
  • 52 Week Low
  • CCNE $19.32
  • ABUS $2.71
  • 52 Week High
  • CCNE $29.29
  • ABUS $5.10
  • Technical
  • Relative Strength Index (RSI)
  • CCNE 41.97
  • ABUS 52.93
  • Support Level
  • CCNE $23.49
  • ABUS $4.25
  • Resistance Level
  • CCNE $25.83
  • ABUS $4.66
  • Average True Range (ATR)
  • CCNE 0.74
  • ABUS 0.17
  • MACD
  • CCNE -0.22
  • ABUS -0.04
  • Stochastic Oscillator
  • CCNE 26.33
  • ABUS 33.33

About CCNE CNB Financial Corporation

CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: